Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Sales: 2017-2025

Historic Return on Sales for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to -0.92%.

  • Ultragenyx Pharmaceutical's Return on Sales rose 15.00% to -0.92% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.92%, marking a year-over-year increase of 15.00%. This contributed to the annual value of -1.02% for FY2024, which is 38.00% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Return on Sales of -0.92% as of Q3 2025, which was down 5.25% from -0.88% recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Return on Sales registered a high of -0.62% during Q1 2021, and its lowest value of -1.98% during Q3 2022.
  • Its 3-year average for Return on Sales is -1.28%, with a median of -1.22% in 2024.
  • Its Return on Sales has fluctuated over the past 5 years, first skyrocketed by 287bps in 2021, then slumped by 98bps in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Return on Sales (Quarterly) stood at -1.30% in 2021, then slumped by 66bps to -1.96% in 2022, then soared by 56bps to -1.40% in 2023, then spiked by 38bps to -1.02% in 2024, then increased by 15bps to -0.92% in 2025.
  • Its Return on Sales was -0.92% in Q3 2025, compared to -0.88% in Q2 2025 and -0.93% in Q1 2025.